RESERPINE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for reserpine and what is the scope of freedom to operate?
Reserpine
is the generic ingredient in thirteen branded drugs marketed by Novartis, Lilly, Bowman Pharms, Bristol Myers Squibb, Barr, Bell Pharma, Bundy, Cycle, Elkins Sinn, Everylife, Halsey, Hikma Intl Pharms, Impax Labs, Ivax Sub Teva Pharms, Marshall Pharma, Mk Labs, Mylan, Pharmavite, Purepac Pharm, Pvt Form, Rexall, Sandoz, Solvay, Tablicaps, Teva, Valeant Pharm Intl, Watson Labs, Whiteworth Town Plsn, Lannett, Panray, Vale, Vitarine, Sanofi Aventis Us, and Schering, and is included in forty-three NDAs. Additional information is available in the individual branded drug profile pages.There are nineteen drug master file entries for reserpine.
Summary for RESERPINE
| US Patents: | 0 |
| Tradenames: | 13 |
| Applicants: | 34 |
| NDAs: | 43 |
| Drug Master File Entries: | 19 |
| Raw Ingredient (Bulk) Api Vendors: | 101 |
| Clinical Trials: | 13 |
| Patent Applications: | 8,383 |
| DailyMed Link: | RESERPINE at DailyMed |
Recent Clinical Trials for RESERPINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mansoura University | Phase 4 |
| Mayo Clinic | Phase 1 |
| University of Alabama at Birmingham | Phase 2 |
Medical Subject Heading (MeSH) Categories for RESERPINE
Anatomical Therapeutic Chemical (ATC) Classes for RESERPINE
US Patents and Regulatory Information for RESERPINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Watson Labs | TRICHLORMETHIAZIDE W/ RESERPINE | reserpine; trichlormethiazide | TABLET;ORAL | 085248-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bell Pharma | RESERPINE | reserpine | TABLET;ORAL | 083058-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sandoz | RESERPINE | reserpine | TABLET;ORAL | 009838-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pharmavite | RESERPINE | reserpine | TABLET;ORAL | 084663-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | SERPASIL | reserpine | TABLET;ORAL | 009115-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Schering | NAQUIVAL | reserpine; trichlormethiazide | TABLET;ORAL | 012265-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sandoz | RESERPINE | reserpine | TABLET;ORAL | 009838-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
